Hemoadsorption Therapy in Critically Ill Adults
Official title: Hemodynamic, Laboratory, and Clinical Outcomes of Hemoadsorption theraPy: an obsErvational Study at Flór Ferenc Hospital Using Longitudinal Data (HOPE-FUL)
Run by Pest County Flór Ferenc Hospital · NCT07679555 · Data updated 2026-11-12
This study looks at whether adding CytoSorb or Efferon LPS hemoadsorption after starting vasopressors helps stabilize critically ill adults in Hungary.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Pest County Flór Ferenc Hospital Academic / other |
| Locations | 1 site (Kistarcsa, Pest County) |
| Status | Recruiting |
| Started | January 1, 2020 |
| Main results expected | May 31, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | July 7, 2026 |
| Trial ID | NCT07679555 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 years who received CytoSorb or Efferon LPS hemoadsorption with available pre- and post-treatment data.
✕Probably not a fit
Patients lacking key data or who did not receive the specified hemoadsorption devices may not show benefit in this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center retrospective observational study conducted at Flór Ferenc Hospital in Kistarcsa, Hungary. It analyzes adult ICU patients who received CytoSorb or Efferon LPS hemoadsorption between January 1, 2020 and May 31, 2026. The researchers will compare pre- and post-treatment data on vasopressor needs, hemodynamics, inflammatory and liver biomarkers, tissue perfusion, and oxygenation, and will report ICU length of stay as well as ICU, 28-day, and 90-day mortality. No interventions are performed as part of the study; data are collected from anonymized medical records. The goal is to clarify how hemoadsorption might affect outcomes in septic shock and other hyperinflammatory states.
Why it matters
Potential benefit: If positive, results could help define when hemoadsorption might benefit critically ill patients and guide clinical decision-making.
How similar studies have gone: Previous studies on hemoadsorption have shown mixed results, making further data in real-world settings valuable but not yet definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>18 years; * CytoSorb or Efferon LPS hemoadsorption treatment, * with available relevant pre- and post-treatment clinical and laboratory data Exclusion Criteria: * age under 18 years * missing key demographic or outcome data; * unknown treatment type or timing; * data unavailable for legal or ethical reasons.
Where it's running
-
Pest County Flór Ferenc Hospital, Dept. of Anaesthesiology and Intensive Therapy
Kistarcsa, Pest County, Hungary Recruiting
Study contacts
- Study coordinator: Zoltán Ruszkai, MD, PhD
- Email: ruszkai.zoltan@florhosp.hu
- Phone: 0036209151978
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oxiris filter: how it removes cytokines and endotoxin in septic shock
This will test whether the Oxiris hemofilter keeps removing endotoxins and inflammatory proteins over 24 hours in adults with septic shock who need continuous kidney support.
-
Hemoadsorption for Severe Ischemic Stroke
This trial tests whether adding hemoadsorption to standard stroke care helps people with severe ischemic stroke recover better than standard care alone.
-
EIT versus dynamic compliance guidance for setting PEEP during laparoscopic gynecological surgery
This trial tests whether using electrical impedance tomography (EIT) to set PEEP works better than using dynamic lung compliance for adults having elective laparoscopic gynecological surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.